# US 2010/0305039 A1 · Production of collagen in the milk of transgenic mammals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305039 A1
- Document ID: US20100305039A1
- Status: Published application
- Kind: A1
- Application number: 12/268,412
- Filed: 2008-11-10
- Published: 2010-12-02
- Earliest claimed: 1994-07-27
- Assignees: Pharming Intellectual Property B.V.; Cohesion Technologies, Inc.; Gene Pharming Europe B.V.; Collagen Corporation
- Inventors: Costas N. Karatzas; Frank Pieper; Ineke De Wit; Richard Berg; Gerard Platenburg; Paul David Toman
- Web page: https://patentgrep.com/patent/US20100305039A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- A23C 9/20: Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23J 1/20: from milk, e.g. casein (curds or cheese A23C); from whey
- A23J 3/06: Gelatine
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A01K 2207/15: Humanized animals
- A01K 2217/00: Genetically modified animals
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/10: Mammal
- A01K 2227/101: Bovine
- A01K 2227/105: Murine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- C07K 2319/02: containing a signal sequence
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A23J: PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

A procollagen or collagen protein, wherein 7-27% of proline residues of the protein are hydroxylated, and/or 0-5% of lysine residues of the protein are hydroxylated.

### Claim 35 (depends on 34)

The protein of claim 34 in purified form.

### Claim 36 (depends on 34)

The protein of claim 34 that is procollagen.

### Claim 37 (depends on 34)

The protein of claim 34 that is collagen.

### Claim 38 (depends on 34)

The protein of claim 34, wherein 7-27% of proline residues of the protein are hydroxylated and 0-5% of lysine residues of the protein are hydroxylated.

### Claim 39 (depends on 34)

The protein of claim 34, wherein 7-27% of proline residues in the protein are hydroxylated.

### Claim 40 (depends on 34)

The procollagen or collagen of claim 34 in trimeric form.

### Claim 41 (depends on 34)

The procollagen or collagen of claim 34 in homotrimeric form.

### Claim 42 (depends on 46)

The procollagen or collagen protein of claim 46 associated with another type of procollagen or collagen protein in heterotrimeric form.

### Claim 43 (depends on 34)

The protein of claim 34, wherein the protein is human.

### Claim 44 (depends on 34)

The protein of claim 34 that is proα1(I).

### Claim 45 (depends on 34)

The protein of claim 34 produced by
(a) providing a transgenic nonhuman mammal having a transgene comprising:
(i) a mammary-gland specific promoter;
(ii) a mammary-gland specific enhancer;
(iii) a secretory DNA segment encoding a signal peptide functional in mammary secretory cells of the transgenic nonhuman mammal; and
(iv) a recombinant DNA segment encoding an exogenous procollagen polypeptide operably linked to the secretory DNA segment to form a secretory-recombinant DNA segment, the secretory-recombinant DNA segment being operably linked to the promoter and to the enhancer;
wherein the transgene, in an adult form of the nonhuman mammal or a female descendant of the nonhuman mammal, expresses the secretory-recombinant DNA segment in the mammary secretory cells to produce a form of the exogenous procollagen polypeptide that is processed and secreted by the mammary secretory cells into milk as exogenous procollagen or collagen in a detectable amount;
(c) recovering milk from the adult form of the transgenic nonhuman mammal or its female descendant, wherein the milk comprises exogenous procollagen or collagen in a recoverable amount; and
(d) purifying the procollagen or collagen from the milk.

### Claim 46

In a method of treating a patient using procollagen or collagen protein, the improvement wherein 7-27% of proline residues of the protein are hydroxylated, and/or 0-5% of lysine residues of the protein are hydroxylated.

### Claim 47 (depends on 46)

The method of claim 46, wherein the polypeptide is crosslinked before administration into the patient.

### Claim 48 (depends on 46)

The method of claim 46, wherein the polypeptide is crosslinked after administration into the patient.

### Claim 49 (depends on 46)

The method of claim 46 comprising injecting the procollagen or collagen into the patient to correct a defect in a soft tissue.

### Claim 50 (depends on 46)

The method of claim 46, wherein the method is selected from the group consisting of correcting defects in soft tissues, reconstructive surgery, restoring defects in bone, enhancing bone growth, repairing cartilage damage, inducing tolerance to rheumatoid arthritis, cardiovascular surgery, thoracic surgery, neurosurgery, and stabilizing an agent in a drug delivery system.
